Study of Tolododekin Alfa with immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, Tolododekin Alfa, combined with an immunotherapy drug for advanced non-small cell lung cancer. It aims to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic non-small cell lung cancer.
- Your overall health should be good enough to perform daily activities (ECOG score 0-1).
- You must have tumors that can be measured on scans.
- You should not have certain gene mutations (EGFR or ALK).
- You need to be willing to provide a fresh tumor biopsy sample.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.